Carisma Therapeutics Inc. (CARM NASDAQ) stock market data APIs
$0.0367
0.01(27.2%)
as of October 17, 2025
Try our APIs with
free plan!
Carisma Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Prev. Close
0.0367
Open
0.0448
High
0.0488
Low
0.0347
52 wk Range
0.026-1.27
Market Cap
6 431 K
Shares Outstanding
41 788 K
Revenue
10 767 K
EPS
-0.23
Beta
3.808
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Carisma Therapeutics Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Carisma Therapeutics Inc. data using free add-ons & libraries
Get Carisma Therapeutics Inc. Fundamental Data
Carisma Therapeutics Inc. Fundamental data includes:
- Net Revenue: 10 767 K
- EBITDA: -42 044 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.53
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Carisma Therapeutics Inc. News
New
Successful Completion of Tender Offer on Carmila’s Bonds With €313,100,000 of Bonds Tendered
PARIS, October 10, 2025--(BUSINESS WIRE)--Regulatory News: Carmila (Paris:CARM) successfully completed its tender offer, announced on 02 October 2025, on the following series of existing notes: €3...
Carmila: Information Concerning the Total Number of Voting Rights and Share
Provided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the Règlement généralde l’Autorité des marchés financiers (General regulation of t...
Carmila: Successful €300 Million Green Bond Issue Maturing in January 2033 With an Annual Fixed Coupon of 3.75%
PARIS, October 02, 2025--(BUSINESS WIRE)--Regulatory News: Carmila (Paris:CARM) has successfully completed a €300 million green bond issue with a slightly above 7-year maturity (13 January 2033) an...
Carmila Announces the Launch of a Tender Offer on Its Existing Notes Maturing in May 2027, March 2028, October 2028 and April 2029, and Announces Its Intention to Issue New Notes
PARIS, October 02, 2025--(BUSINESS WIRE)--Regulatory News: Carmila (Paris:CARM) announces today the launch of a tender offer on the following series of existing notes: €300,000,000 at 1.625 per ce...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
